Blog | Calvine Partners

Andrew Keith

Jul 6, 2021

Basilea - Lisavanbulin shows further promise

Brian White

Jul 2, 2021

Diurnal Group receives UK marketing approval for Efmody

Andrew Keith

Jun 30, 2021

Five reasons to invest in healthcare and biotechnology

Brian White

Jun 29, 2021

Diurnal Group - Er-Kim distribution agreement

Brian White

Jun 7, 2021

Basilea - Lisavanbulin ASCO presentation

Andrew Keith

Jun 3, 2021

Diurnal Group - Globalisation of the adrenal franchise

Brian White

May 12, 2021

Diurnal significantly increases exposure to the Chinese market

Andrew Keith

May 6, 2021

Basilea - The bacteraemia opportunity

Andrew Keith

Mar 26, 2021

Diurnal Group - Efmody (Chronocort) recommended for approval in EU

Brian White

Mar 5, 2021

Basilea - Amgen to acquire Five Prime Therapeutics for $1.9bn

Andrew Keith

Mar 3, 2021

Diurnal Group - A new dawn

Andrew Keith

Feb 22, 2021

Basilea's lisavanbulin

Brian White

Feb 12, 2021

Basilea reports further detail on derazantinib/checkpoint inhibitor combination

Brian White

Feb 10, 2021

Basilea reports positive results for derazantinib in biliary cancer

Brian White

Feb 9, 2021

Further good news from Basilea's Cresemba

Brian White

Feb 2, 2021

Diurnal Group JCEM publication

Andrew Keith

Jan 18, 2021

Diurnal Group and Chronocort

Brian White

Jan 14, 2021

Diurnal Business Update

Brian White

Jan 11, 2021

Basilea preliminary 2020 revenue and portfolio progress

Andrew Keith

Dec 21, 2020

Basilea - Lisavanbulin shows further promise

Diurnal Group receives UK marketing approval for Efmody

Five reasons to invest in healthcare and biotechnology

Diurnal Group - Er-Kim distribution agreement

Basilea - Lisavanbulin ASCO presentation

Diurnal Group - Globalisation of the adrenal franchise

Diurnal significantly increases exposure to the Chinese market

Basilea - The bacteraemia opportunity

Diurnal Group - Efmody (Chronocort) recommended for approval in EU

Basilea - Amgen to acquire Five Prime Therapeutics for $1.9bn

Diurnal Group - A new dawn

Basilea's lisavanbulin

Basilea reports further detail on derazantinib/checkpoint inhibitor combination

Basilea reports positive results for derazantinib in biliary cancer

Further good news from Basilea's Cresemba

Diurnal Group JCEM publication

Diurnal Group and Chronocort

Diurnal Business Update

Basilea preliminary 2020 revenue and portfolio progress

Basilea's derazantinib - a differentiated FGFR inhibitor

Calvine Partners LLP is authorised and regulated by the Financial Conduct Authority